US

Kris Kowdley, MD, contributed significantly to the clinical research program that led to accelerated FDA approval of Ipsen’s Iqirvo, a first-in-class treatment for primary biliary cholangitis (PBC), a rare liver disease. As a primary investigator for the Phase 3 ELATIVE trial, Dr. Kowdley’s site enrolled the first patient in the study, and he was the … Read more

Velocity Clinical Research, the leading multi-specialty clinical sites business, and Luminis Health, a nonprofit health system providing care for 1.8 million people, today announce their partnership to conduct clinical research within the health group’s organization, connecting more patients with community-based research programs. The partnership will involve Velocity taking over operation of the hospital’s existing clinical … Read more

It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA, Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council, discusses their importance to patients yesterday, today, and tomorrow.  Dr. Cromwell is board-certified in Family Medicine and Clinical Lipidology with over 20 years of clinical research experience.  As he … Read more

Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a … Read more

Velocity has made an incredible impact over the past year! Our sites conducted clinical trials that supported 12 U.S. product approvals in 2023, contributing to the betterment of global health. To date, Velocity has contributed to research programs for over 50 product approvals. From pioneering vaccines to cutting-edge drugs, Velocity’s team worldwide has worked diligently … Read more

Six Velocity Principal Investigators coauthored an article recently published in Nature Medicine. The article covers the results of a Phase 2/3 trial of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Beyond yielding promising results, the trial has set the groundwork for swiftly addressing circulating variants as SARS-CoV-2 continues … Read more

After battling on the frontline for many years against an aggressive and elusive opponent, Michael Hemphill, MD and the Velocity team in Savannah, GA, believe we’ve entered an exciting “new era” in the fight against Alzheimer’s disease and dementia. Velocity conducts clinical trials related to disorders of the nervous system in Savannah as an embedded research … Read more

Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.  Alzheimer’s disease, a cruel and pernicious affliction, is a brain disorder that slowly destroys memory, thinking skills, and eventually, the ability to carry out even the most simple and … Read more